Cite
HARVARD Citation
Ascierto, P. et al. (2023). Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial. Journal of clinical oncology. 41 (2), pp. 212-221. [Online].